10x Genomics (TXG) Stock Falls on Q1 2026 Earnings

10x Genomics (TXG) reported first-quarter 2026 results with mixed revenue performance and continued pressure on profitability.

Revenue: $150.8 million (down 2.6% year-over-year).

Gross profit: $106.2 million (up 0.7% year-over-year).

Operating result: operating loss of $(17.0 million) (operating profit decreased 56.7% year-over-year).

Net loss attributable to common shareholders: $(13.5 million) (loss widened 60.8% year-over-year).

Diluted EPS: $(0.10) per share (down 64.3% year-over-year).

Cash flow and balance sheet highlights:

Cash from operating activities: $40.8 million (up 18.7% year-over-year).

Purchases of property, plant and equipment: $(1.8 million) (down 6.1% year-over-year).

Cash and cash equivalents: $490.3 million (up 30.0% year-over-year).

Total liabilities: $201.4 million (up 2.5% year-over-year).

Analyst expectations and market reaction: revenue topped estimates at $150.8 million versus an expectation of $147.8 million, while EPS came in at $(0.10) versus an estimate of $(0.29); shares moved -8.21% after the close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

10x Genomics Inc. Insider Trading Activity

10x Genomics Inc. insiders have traded $TXG stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:

SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 7 sales selling 59,045 shares for an estimated $1,209,653.
ADAM TAICH (Chief Financial Officer) has made 0 purchases and 2 sales selling 20,856 shares for an estimated $392,444.
BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 16,109 shares for an estimated $302,741.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

10x Genomics Inc. Hedge Fund Activity

We have seen 154 institutional investors add shares of 10x Genomics Inc. stock to their portfolio, and 174 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 4,195,603 shares (-77.2%) from their portfolio in Q4 2025, for an estimated $68,430,284
FMR LLC added 3,459,481 shares (+40.9%) to their portfolio in Q4 2025, for an estimated $56,424,135
WELLINGTON MANAGEMENT GROUP LLP removed 2,836,863 shares (-66.2%) from their portfolio in Q4 2025, for an estimated $46,269,235
BANK OF AMERICA CORP /DE/ removed 1,575,766 shares (-46.2%) from their portfolio in Q4 2025, for an estimated $25,700,743
CASDIN CAPITAL, LLC added 1,400,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $22,834,000
ROYAL BANK OF CANADA removed 1,321,614 shares (-92.4%) from their portfolio in Q4 2025, for an estimated $21,555,524
QUANTINNO CAPITAL MANAGEMENT LP added 1,174,744 shares (+33.6%) to their portfolio in Q4 2025, for an estimated $19,160,074

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

10x Genomics Inc. Government Contracts

We have seen $8,843,695 of award payments to $TXG over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $371,793
GENE EXPRESSION REAGENTS: $334,142
BIOLOGICAL REAGENT MATERIAL - CHROMIUM NEXT GEM SINGLE CELL MULTIOME AND GEM-X SINGLE CELL 5 KITS AND RELAT...: $249,991
REAGENTS FOR ONGOING NGS PROJECTS (AMBIS 2270566): $249,963
IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING - KITS AND REAGENTS USED IN SINGLE-CELL AND GENE PANEL ANALYSES: $249,934

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

10x Genomics Inc. Analyst Ratings

Wall Street analysts have issued reports on $TXG in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 03/31/2026
Canaccord Genuity issued a "Buy" rating on 12/22/2025

To track analyst ratings and price targets for 10x Genomics Inc., check out Quiver Quantitative's $TXG forecast page.

10x Genomics Inc. Price Targets

Multiple analysts have issued price targets for $TXG recently. We have seen 10 analysts offer price targets for $TXG in the last 6 months, with a median target of $22.0.

Here are some recent targets:

Kyle Mikson from Canaccord Genuity set a target price of $32.0 on 04/20/2026
Derik De Bruin from B of A Securities set a target price of $30.0 on 04/20/2026
Luke Sergott from Barclays set a target price of $30.0 on 04/14/2026
Patrick Donnelly from Citigroup set a target price of $24.0 on 04/07/2026
Daniel Arias from Stifel set a target price of $25.0 on 03/02/2026
Dan Leonard from UBS set a target price of $20.0 on 02/20/2026
Dan Brennan from TD Cowen set a target price of $19.0 on 02/13/2026